知搜-全球专利检索

  1. 登录
  2. 注册
发明公开
CN101687034A 含有识别HLAI类的抗体作为有效成分的化疗药物耐药性癌症的治疗剂及其应用 无效 - 撤回

含有识别HLAI类的抗体作为有效成分的化疗药物耐药性癌症的治疗剂及其应用
摘要：
本发明人等明确了：在高表达MDR1和HLA I类A蛋白质的化疗药物耐药性血液肿瘤细胞株中，与亲本株相比，以低浓度诱导C3B3双抗体带来的细胞毒活性。另外明确了：如果对该化疗药物耐药性血液肿瘤细胞株进行C3B3双抗体前处理，则化疗药物单独引起的细胞损伤增强，细胞中的药物摄入量增加。即，发现了：对于高表达HLA I类的MDR1表达肿瘤细胞，C3B3双抗体发挥抗肿瘤活性，并具有克服抗药性的作用。
摘要（英）：

It has been clarified that the cytotoxic activity of C3B3 diabody is induced at a lower concentration in a chemotherapy-resistant blood tumor cell line overexpressing MDR1 and HLA class IA proteins than in the parent strain. It has been also clarified that when this chemotherapy-resistant blood tumor cell line is pretreated with C3B3 diabody, the cytotoxic activity of the chemotherapeutic drug alone is enhanced and the drug is incorporated in an increased amount into the cells. Namely, it has been found out that C3B3 diabody exerts an antitumor activity on MDR1-expressing tumor cells overexpressing HLA class I and has an effect of overcoming the drug resistance.

0/0